- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Acuson exhibits IVUS catheter at AHA show
Acuson of Mountain View, CA, demonstrated a 64-channel intravascular ultrasound catheter as a work-in-progress for cardiac imaging at last month's American Heart Association meeting in Dallas. The company believes that the side-fire catheter should be
Acuson of Mountain View, CA, demonstrated a 64-channel intravascular ultrasound catheter as a work-in-progress for cardiac imaging at last month's American Heart Association meeting in Dallas. The company believes that the side-fire catheter should be more versatile than one-channel IVUS catheters.
The catheter is placed in the right atrium for intracardiac imaging and provides better image quality than a transthoracic or transesophageal probe, according to the company. It supports color Doppler, Doppler Tissue Imaging, spectral imaging, and almost all imaging techniques available on the Aspen or Sequoia scanners.
Acuson has an investigational device exemption for the transducer and is conducting clinical trials for the probe. The company plans to file a 510(k) application next year.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
